Skip to content

Study · Non-randomized trial · n = 6 · 2007

3 results

Effect of one month ketoconazole treatment on GH, cortisol and ACTH release after ghrelin, GHRP-6 and GHRH administration in patients with Cushing's disease.

Correa-Silva SR, Nascif SO, Silva MR, Molica P, Lengyel AM

Arquivos brasileiros de endocrinologia e metabologia1 Oct 2007Cited by 5 (Europe PMC)

PMID18157387 (opens in a new tab)DOI10.1590/s0004-27302007000700014 (opens in a new tab)PepBankPUB-18157387
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialActivity measurement

    In patients with Cushing's disease, peak GH after GHRP‑6 before ketoconazole was 3.8 +/- 1.6 microg/L.

    In plain wordsIn patients with Cushing's disease, peak growth hormone after GHRP‑6 before ketoconazole was 3.8 +/- 1.6 microg/L.

    Peptide
    GHRP-6
    Outcome
    Not applicablePeak GH after GHRP-6 before ketoconazole
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Peak GH
    3.8 microg/L
    Before ketoconazole, after GHRP-6

    Source sentences

    Summary
    Before treatment peak GH (microg/L; mean +/- SEM) after ghrelin, GHRP-6, and GHRH administration was 10.0 +/- 4.5; 3.8 +/- 1.6, and 0.6 +/- 0.2, respectively.
    1 context sentence
    Summary · context
    The aims of this study were to compare the GH response to ghrelin, GHRP-6, and GHRH, and the ACTH and cortisol responses to ghrelin and GHRP-6 before and after one month of ketoconazole treatment in 6 untreated patients with CD.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 02HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement

    In patients with Cushing's disease, ketoconazole did not significantly change GH responses to GHRP‑6.

    In plain wordsIn patients with Cushing's disease, growth hormone responses to GHRP‑6 did not change significantly after ketoconazole compared with before treatment.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRP-6 after ketoconazole
    Study

    n = 6

    Comparator
    Before ketoconazole treatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak GH
    3.8 microg/L
    Before ketoconazole, after GHRP-6
    Peak GH
    3.1 microg/L
    After ketoconazole, after GHRP-6

    Source sentences

    Summary
    After one month of ketoconazole there was a significant decrease in urinary cortisol values (mean reduction: 75%), but GH responses did not change (7.0 +/- 2.0; 3.1 +/- 0.8; 0.9 +/- 0.2, respectively).
    2 context sentences
    Summary · context
    Before treatment peak GH (microg/L; mean +/- SEM) after ghrelin, GHRP-6, and GHRH administration was 10.0 +/- 4.5; 3.8 +/- 1.6, and 0.6 +/- 0.2, respectively.
    Summary · context
    The aims of this study were to compare the GH response to ghrelin, GHRP-6, and GHRH, and the ACTH and cortisol responses to ghrelin and GHRP-6 before and after one month of ketoconazole treatment in 6 untreated patients with CD.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 03HumanNot a test of GHRP-6 aloneNon-randomized trialActivity measurement

    In patients with Cushing's disease, ketoconazole did not significantly change ACTH responses to GHRP‑6.

    In plain wordsIn patients with Cushing's disease, ACTH responses to GHRP‑6 did not change significantly after ketoconazole compared with before treatment.

    Peptide
    GHRP-6
    Outcome
    No significant changeACTH response to GHRP-6 after ketoconazole
    Study

    n = 6

    Comparator
    Before ketoconazole treatment
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    ACTH
    199.8 pg/mL
    Before ketoconazole, GHRP-6 response
    ACTH
    227 pg/mL
    After ketoconazole, GHRP-6 response

    Source sentences

    Summary
    No significant changes in ACTH (pg/mL) responses before (ghrelin: 210.9 +/- 69.9; GHRP-6: 199.8 +/- 88.8) and after treatment (ghrelin: 159.7 +/- 40.3; GHRP-6: 227 +/- 127.2) were observed.
    1 context sentence
    Summary · context
    The aims of this study were to compare the GH response to ghrelin, GHRP-6, and GHRH, and the ACTH and cortisol responses to ghrelin and GHRP-6 before and after one month of ketoconazole treatment in 6 untreated patients with CD.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    21 Oct 2026, 15:58 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.